Results 151 to 160 of about 3,836,410 (303)

Determinants of Body Mass Index in Early Systemic Sclerosis: Implications for Nutritional Risk Stratification

open access: yesArthritis Care &Research, EarlyView.
Objective Gastrointestinal (GI) involvement can lead to malnutrition in patients with systemic sclerosis (SSc). Body mass index (BMI) remains the most widely used marker to screen nutritional status. We aimed to identify predictors of lower BMI in patients with SSc. Methods Patients with SSc from a prospective US cohort meeting 2013 American College of
Ali Y. Ayla   +8 more
wiley   +1 more source

Differential expression of immune checkpoint VISTA in inflammatory skin diseases. [PDF]

open access: yesJ Invest Dermatol
Jaiswal A   +7 more
europepmc   +1 more source

Antibiotics in skin disease.

open access: yesSouth African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2000
No ...
openaire   +2 more sources

Engagement Patterns With an Artificial Intelligence Health Coach for Systemic Sclerosis Self‐Management: A Mixed Methods Study

open access: yesArthritis Care &Research, EarlyView.
Objective To evaluate utility of an artificial intelligence (AI) health coach for systemic sclerosis (SSc) self‐management and identify patterns associated with participant engagement. Methods We conducted a mixed methods study in which an AI health coach, powered by a large language model (LLM), was used to support self‐management for SSc.
Nirali Shah   +4 more
wiley   +1 more source

Coloured plates for the new edition of Wilson on the skin.

open access: yes
[A separately-issued atlas for his On diseases of the skin (Philadelphia, 1847)]Cover title.Mode of access ...
Wilson, Erasmus, Sir, 1809-1884.   +1 more
core  

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis

open access: yesArthritis Care &Research, EarlyView.
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy